Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Daniele Generali(University of Trieste), Stannie J. van den Ende(Agendia (Netherlands)), Giulia Fornaro(Bocconi University), Fabiola Giudici(University of Padua), Darina Pronin(Agendia (Netherlands)), Carlo Azzini(Istituti Ospitalieri di Cremona), Andrea Rocca(University of Trieste), Enrico Fiorino(University of Trieste), Valeria Cervoni(University of Trieste), Sergio Aguggini(Istituti Ospitalieri di Cremona), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Marzia Alberio(Istituti Ospitalieri di Cremona), Martina Dester(Istituti Ospitalieri di Cremona), Manuela Milani(Humanitas University), Antonella Saracino(Istituti Ospitalieri di Cremona), Oriana Ciani(Bocconi University), Ingnazio Ciliberto(Istituti Ospitalieri di Cremona), Christa Dreezen(Leiden University Medical Center)
Cited by 1
Related Papers
Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
|Journal of Clinical Oncology|2010|541
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268